Inventor
SCHLOTHAUER TILMAN
DE33 patents
⚠️ This page may combine multiple inventors who share the name “SCHLOTHAUER TILMAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
31 patentsUS10323089B2Jun 18, 2019
Anti-transferrin receptor antibodies with tailored affinity
HOFFMANN LA ROCHE25 citations94
US10683368B2Jun 16, 2020
Fc-region variants with modified FcRn-binding and methods of use
HOFFMANN LA ROCHE13 citations86
US11584793B2Feb 21, 2023
Anti-transferrin receptor antibodies with tailored affinity
HOFFMANN LA ROCHE8 citations85
US11286300B2Mar 29, 2022
Humanized anti-human CD19 antibodies and methods of use
HOFFMANN LA ROCHE11 citations85
US11091541B2Aug 17, 2021
Human FcRn-binding modified antibodies and methods of use
HOFFMANN LA ROCHE6 citations84
US10011644B2Jul 3, 2018
Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
HOFFMANN LA ROCHE9 citations84
US10822402B2Nov 3, 2020
Humanized anti-tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE4 citations83
US9862763B2Jan 9, 2018
Humanized anti-tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE4 citations83
US10287352B2May 14, 2019
Bispecific antibodies specific for PD1 and TIM3
HOFFMANN LA ROCHE10 citations82
US12252533B2Mar 18, 2025
Anti-transferrin receptor antibodies with tailored affinity
HOFFMANN LA ROCHE1 citations74
US11555067B2Jan 17, 2023
Fc-region variants with improved protein A-binding
HOFFMANN LA ROCHE3 citations73
US11525007B2Dec 13, 2022
Antibody fab and Fc variants
HOFFMANN LA ROCHE3 citations72
US11130810B2Sep 28, 2021
Bispecific antibodies specific for PD1 and TIM3
HOFFMANN LA ROCHE4 citations71
US10434184B2Oct 8, 2019
Anti-TPBG antibodies and methods of use
HOFFMANN LA ROCHE3 citations70
US12264196B2Apr 1, 2025
Fc-receptor binding modified asymmetric antibodies and methods of use
HOFFMANN LA ROCHE1 citations64
US12398203B2Aug 26, 2025
Method for producing bispecific antibodies comprising a Y436A Fc-region mutation for improved protein A-binding
HOFFMANN LA ROCHE0 citations62
US12297263B2May 13, 2025
Humanized anti-Tau(PS422) antibodies and methods of use
HOFFMANN LA ROCHE0 citations62
US12215152B2Feb 4, 2025
Humanized anti-human CD19 antibodies and methods of use
HOFFMANN LA ROCHE0 citations62
US11572404B2Feb 7, 2023
Humanized anti-Tau(pS422) antibodies and methods of use
HOFFMANN LA ROCHE0 citations62
US11440971B2Sep 13, 2022
Fc-region variants with modified FcRn-binding and methods of use
HOFFMANN LA ROCHE0 citations62
US12522637B2Jan 13, 2026
Complement factor based affinity chromatography
HOFFMANN LA ROCHE0 citations61
US12391757B2Aug 19, 2025
Bispecific antibodies specific for PD1 and TIM3
HOFFMANN LA ROCHE0 citations61
US11440942B2Sep 13, 2022
Complement factor based affinity chromatography
HOFFMANN LA ROCHE0 citations61
US12466872B2Nov 11, 2025
Method for the generation of an FCRN expressing cell by targeted integration of multiple expression cassettes in a defined organization
HOFFMANN LA ROCHE0 citations56
US12103967B2Oct 1, 2024
Bispecific anti-CCL2 antibodies
HOFFMANN LA ROCHE0 citations56
US11739142B2Aug 29, 2023
Bispecific anti-CCL2 antibodies
HOFFMANN LA ROCHE1 citations56
US10899846B2Jan 26, 2021
Fc-region variants with modified FcRn- and protein A-binding properties
HOFFMANN LA ROCHE0 citations52
US10093714B1Oct 9, 2018
Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
HOFFMANN LA ROCHE1 citations52
US9403896B2Aug 2, 2016
Serpin-finger fusion polypeptide
HOFFMANN LA ROCHE0 citations52
US11814409B2Nov 14, 2023
Fc-receptor based affinity chromatography
HOFFMANN LA ROCHE0 citations50
US12461109B2Nov 4, 2025
Vitro prediction of in vivo half-life
HOFFMANN LA ROCHE0 citations46